Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and raises the price target from $27 to $60.